269 related articles for article (PubMed ID: 33668361)
21. Interleukin-2 and Oncolytic Virotherapy: A New Perspective in Cancer Therapy.
Aghbash PS; Rasizadeh R; Yari AH; Lahouti S; MotieGhader H; Nahand JS; Entezari-Maleki T; Baghi HB
Anticancer Agents Med Chem; 2023; 23(18):2008-2026. PubMed ID: 37497707
[TBL] [Abstract][Full Text] [Related]
22. Nanotherapeutics for multiple myeloma.
Zheleznyak A; Shokeen M; Achilefu S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Nov; 10(6):e1526. PubMed ID: 29701006
[TBL] [Abstract][Full Text] [Related]
23. [Advances in combination strategies with oncolytic virotherapy].
Zhai ZL; Shen YN; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2023 Oct; 61(10):923-928. PubMed ID: 37653997
[TBL] [Abstract][Full Text] [Related]
24. Targeting Biophysical Cues: a Niche Approach to Study, Diagnose, and Treat Cancer.
Zhang SX; Liu L; Zhao W
Trends Cancer; 2018 Apr; 4(4):268-271. PubMed ID: 29606309
[TBL] [Abstract][Full Text] [Related]
25. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.
Holstein SA; Asimakopoulos F; Azab AK; Bianchi G; Bhutani M; Crews LA; Cupedo T; Giles H; Gooding S; Hillengass J; John L; Kaiser S; Lee L; Maclachlan K; Pasquini MC; Pichiorri F; Shah N; Shokeen M; Shy BR; Smith EL; Verona R; Usmani SZ; McCarthy PL
Transplant Cell Ther; 2022 Aug; 28(8):446-454. PubMed ID: 35605882
[TBL] [Abstract][Full Text] [Related]
26. Impact of Clonal Heterogeneity in Multiple Myeloma.
Schinke C; Rasche L; Raab MS; Weinhold N
Hematol Oncol Clin North Am; 2024 Apr; 38(2):461-476. PubMed ID: 38195308
[TBL] [Abstract][Full Text] [Related]
27. Polycytidine tract deletion from microRNA-detargeted oncolytic Mengovirus optimizes the therapeutic index in a murine multiple myeloma model.
Penza V; Maroun JW; Nace RA; Schulze AJ; Russell SJ
Mol Ther Oncolytics; 2023 Mar; 28():15-30. PubMed ID: 36619293
[TBL] [Abstract][Full Text] [Related]
28. Virotherapy in cancer.
Motalleb G
Iran J Cancer Prev; 2013; 6(2):101-7. PubMed ID: 25250118
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic virotherapy targeting the IL15 pathway.
Yoo SY; Heo J
Mol Ther Oncolytics; 2023 Dec; 31():100732. PubMed ID: 37860016
[No Abstract] [Full Text] [Related]
30. The myeloma microenvironment and response to immunotherapy.
Danovi S
Nat Genet; 2023 Dec; 55(12):2018. PubMed ID: 38062103
[No Abstract] [Full Text] [Related]
31. Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs.
Innao V; Rizzo V; Allegra AG; Musolino C; Allegra A
Curr Oncol; 2020 Dec; 28(1):159-183. PubMed ID: 33704184
[TBL] [Abstract][Full Text] [Related]
32. Advancing oncolytic virus therapy by understanding the biology.
Kaufman HL; Maciorowski D
Nat Rev Clin Oncol; 2021 Apr; 18(4):197-198. PubMed ID: 33686265
[No Abstract] [Full Text] [Related]
33. Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses.
Zhang B; Wang X; Cheng P
Front Oncol; 2020; 10():561372. PubMed ID: 33680911
[TBL] [Abstract][Full Text] [Related]
34.
Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL
Front Immunol; 2021; 12():610042. PubMed ID: 33679747
[TBL] [Abstract][Full Text] [Related]
35. Novel Experimental Drugs for Treatment of Multiple Myeloma.
Offidani M; Corvatta L; Morè S; Olivieri A
J Exp Pharmacol; 2021; 13():245-264. PubMed ID: 33727866
[TBL] [Abstract][Full Text] [Related]
36. GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses.
Hamdan F; Martins B; Feodoroff M; Giannoula Y; Feola S; Fusciello M; Chiaro J; Antignani G; Grönholm M; Ylösmäki E; Cerullo V
Mol Ther Methods Clin Dev; 2021 Mar; 20():625-634. PubMed ID: 33718513
[TBL] [Abstract][Full Text] [Related]
37. Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer.
Kana SI; Essani K
Mol Diagn Ther; 2021 May; 25(3):301-313. PubMed ID: 33713031
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic Foamy Virus - generation and properties of a nonpathogenic replicating retroviral vector system that targets chronically proliferating cancer cells.
Budzik KM; Nace RA; Ikeda Y; Russell SJ
J Virol; 2021 Apr; 95(10):. PubMed ID: 33692205
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
40. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Nooka AK; Weisel K; van de Donk NW; Routledge D; Otero PR; Song K; Quach H; Callander N; Minnema MC; Trudel S; Jackson NA; Ahlers CM; Im E; Cheng S; Smith L; Hareth N; Ferron-Brady G; Brouch M; Montes de Oca R; Paul S; Holkova B; Gupta I; Kremer BE; Richardson P
Future Oncol; 2021 Jun; 17(16):1987-2003. PubMed ID: 33682447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
